Full text is available at the source.
Abstract
Injection of the DC-targeting SARS-CoV-2 mRNA vaccine in mice resulted in substantially higher and durable antigen-specific immunoglobulin-G titres compared to untargeted formulations.
- The engineered virus-like particle targets dendritic cells, which are crucial for effective immune responses.
- Mice receiving the DC-targeting vaccine exhibited stronger cellular immune responses.
- The vaccine provided protection against both SARS-CoV-2 and herpes simplex virus 1 infections.
- DC-targeting may enhance the efficacy of prophylactic and therapeutic vaccines.
Simplified